SAG
TVTX icon

SageView Advisory Group’s Travere Therapeutics TVTX Stock Holding History

SageView Advisory Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$77.8K Buy
+2,036
New +$66.2K ﹤0.01% 912

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SageView Advisory Group's TVTX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Travere Therapeutics (TVTX) in Q4 2025: 2,036 shares worth $77.8K. The stake represents ﹤0.01% of the portfolio and ranks #912 among its holdings.

278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • SageView Advisory Group held 2,036 shares of Travere Therapeutics worth $77.8K as of Q4 2025.
  • Travere Therapeutics was a new SageView Advisory Group position in Q4 2025.
  • Travere Therapeutics made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #912 holding.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.